Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA To Post Safety Reviews Online

By Drug Discovery Trends Editor | June 16, 2010

WASHINGTON (AP) – Doctors and patients will be able to get more up-to-date information about the risks of the latest drugs as federal health regulators begin posting summarized safety reviews online.

Under a new policy, the Food and Drug Administration said it would begin publishing summaries of potential safety issues with recently approved drugs.

The FDA is tasked with reviewing the safety and effectiveness of all prescription drugs before they reach the market. But some side effects only show up after the drugs are launched and taken by millions of patients across the country. Additionally, most drugs are prescribed for alternate uses and patients groups, giving rise to unforeseen safety issues.

“So that changes the whole game because you don’t know if the drug is effective in that population,” said Dr. Robert Boucher, director of FDA’s office of drug surveillance, at a press briefing.

Typically the FDA only alerts the public when there is a pressing safety issue. But the new updates will provide a comprehensive look at the safety of all new medications approved by the FDA.

The FDA’s safety summaries will incorporate side effect reports from doctors, patients and hospitals as well as the FDA’s own original research. The FDA has collected this information for decades but has only shared it with the public in the occasional press release.

The agency plans to publish the summaries on a quarterly basis. Each new drug, including drugs approved back to September 2007, will receive a safety summary within roughly two years of approval, according to the FDA.

“These summaries will provide clear and useful information in a timely manner that can be used by providers and patients to make informed decisions,” said Dr. Robert Ball, a director in FDA’s center for biologics evaluation.

The new policy is legally required by a 2007 law designed to make the agency more transparent and responsive to drug safety issues.

Congress wrote the law in response to the 2004 scandal involving the popular painkiller Vioxx, which was pulled from the market five years after its approval because of links to heart attack and stroke. Critics said lives could have been saved if the agency had alerted the public earlier to the safety questions surrounding the drug.

Date: June 15, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE